An overview of biosimilars

Nagaraj B. Malipatil, Kiran Haridas, Shruthi D. Prithvi

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Biosimilars are surmounting pharmaceutical market from last three decades and sale increasing progressively. Advances in the biotechnology lead to development and discovery of new biological products to treat various life-threatening diseases. Biosimilars are biological drugs that are produced after expiry of the patent of approved innovator. This review attempt to highlight the differences between biosimilars and chemical generics, development stages, issues of concern with the use of biosimilars and need of appropriate regulations for their approval. Generic approach is not scientifically useful to manufacture biosimilars. Biosimilars have more structural complexity, multi-layered manufacturing or scale-up process and risk of immunogenicity; therefore required unique regulatory pathways to introduce them in the market. Safety and efficacy of biosimilar are essential parameter to increase access in the population. Biosimilars can ensure the cost-effective treatment to invade incurable diseases due to enhanced competition in pharma/biotech industries to manufacture it.

Original languageEnglish
Pages (from-to)23-27
Number of pages5
JournalAsian Journal of Pharmaceutical and Clinical Research
Volume8
Issue number5
Publication statusPublished - 01-01-2015
Externally publishedYes

Fingerprint

Biosimilar Pharmaceuticals
Biotechnology
Biological Products
Health Care Costs

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science
  • Pharmacology
  • Pharmacology (medical)

Cite this

Malipatil, N. B., Haridas, K., & Prithvi, S. D. (2015). An overview of biosimilars. Asian Journal of Pharmaceutical and Clinical Research, 8(5), 23-27.
Malipatil, Nagaraj B. ; Haridas, Kiran ; Prithvi, Shruthi D. / An overview of biosimilars. In: Asian Journal of Pharmaceutical and Clinical Research. 2015 ; Vol. 8, No. 5. pp. 23-27.
@article{248bb5d8a8f440fc9c9f82455cb33dad,
title = "An overview of biosimilars",
abstract = "Biosimilars are surmounting pharmaceutical market from last three decades and sale increasing progressively. Advances in the biotechnology lead to development and discovery of new biological products to treat various life-threatening diseases. Biosimilars are biological drugs that are produced after expiry of the patent of approved innovator. This review attempt to highlight the differences between biosimilars and chemical generics, development stages, issues of concern with the use of biosimilars and need of appropriate regulations for their approval. Generic approach is not scientifically useful to manufacture biosimilars. Biosimilars have more structural complexity, multi-layered manufacturing or scale-up process and risk of immunogenicity; therefore required unique regulatory pathways to introduce them in the market. Safety and efficacy of biosimilar are essential parameter to increase access in the population. Biosimilars can ensure the cost-effective treatment to invade incurable diseases due to enhanced competition in pharma/biotech industries to manufacture it.",
author = "Malipatil, {Nagaraj B.} and Kiran Haridas and Prithvi, {Shruthi D.}",
year = "2015",
month = "1",
day = "1",
language = "English",
volume = "8",
pages = "23--27",
journal = "Asian Journal of Pharmaceutical and Clinical Research",
issn = "0974-2441",
publisher = "Innovare Academics Sciences Pvt. Ltd",
number = "5",

}

Malipatil, NB, Haridas, K & Prithvi, SD 2015, 'An overview of biosimilars', Asian Journal of Pharmaceutical and Clinical Research, vol. 8, no. 5, pp. 23-27.

An overview of biosimilars. / Malipatil, Nagaraj B.; Haridas, Kiran; Prithvi, Shruthi D.

In: Asian Journal of Pharmaceutical and Clinical Research, Vol. 8, No. 5, 01.01.2015, p. 23-27.

Research output: Contribution to journalReview article

TY - JOUR

T1 - An overview of biosimilars

AU - Malipatil, Nagaraj B.

AU - Haridas, Kiran

AU - Prithvi, Shruthi D.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Biosimilars are surmounting pharmaceutical market from last three decades and sale increasing progressively. Advances in the biotechnology lead to development and discovery of new biological products to treat various life-threatening diseases. Biosimilars are biological drugs that are produced after expiry of the patent of approved innovator. This review attempt to highlight the differences between biosimilars and chemical generics, development stages, issues of concern with the use of biosimilars and need of appropriate regulations for their approval. Generic approach is not scientifically useful to manufacture biosimilars. Biosimilars have more structural complexity, multi-layered manufacturing or scale-up process and risk of immunogenicity; therefore required unique regulatory pathways to introduce them in the market. Safety and efficacy of biosimilar are essential parameter to increase access in the population. Biosimilars can ensure the cost-effective treatment to invade incurable diseases due to enhanced competition in pharma/biotech industries to manufacture it.

AB - Biosimilars are surmounting pharmaceutical market from last three decades and sale increasing progressively. Advances in the biotechnology lead to development and discovery of new biological products to treat various life-threatening diseases. Biosimilars are biological drugs that are produced after expiry of the patent of approved innovator. This review attempt to highlight the differences between biosimilars and chemical generics, development stages, issues of concern with the use of biosimilars and need of appropriate regulations for their approval. Generic approach is not scientifically useful to manufacture biosimilars. Biosimilars have more structural complexity, multi-layered manufacturing or scale-up process and risk of immunogenicity; therefore required unique regulatory pathways to introduce them in the market. Safety and efficacy of biosimilar are essential parameter to increase access in the population. Biosimilars can ensure the cost-effective treatment to invade incurable diseases due to enhanced competition in pharma/biotech industries to manufacture it.

UR - http://www.scopus.com/inward/record.url?scp=84940932765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940932765&partnerID=8YFLogxK

M3 - Review article

VL - 8

SP - 23

EP - 27

JO - Asian Journal of Pharmaceutical and Clinical Research

JF - Asian Journal of Pharmaceutical and Clinical Research

SN - 0974-2441

IS - 5

ER -

Malipatil NB, Haridas K, Prithvi SD. An overview of biosimilars. Asian Journal of Pharmaceutical and Clinical Research. 2015 Jan 1;8(5):23-27.